Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.89 |
| ▸ | LTA4H | P09960 | 2/20 | 0.79 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
| ▸ | HRH2 | P25021 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491607 | 0.98 | HRH3 (0.86) | HRH3LTA4HPTGS2PTGS1KDM4E | |
| SCHEMBL21814264 | 0.98 | HRH3 (0.86) | HRH3LTA4HPTGS2PTGS1KDM4E | |
| SCHEMBL5856034 | 0.97 | HRH3 (0.84) | HRH3LTA4HPTGS2PTGS1KDM4E | |
| SCHEMBL4994427 | 0.94 | HRH3 (0.94) | HRH3LTA4HPTGS2PTGS1KDM4E | |
| SCHEMBL490968 | 0.94 | HRH3 (1.00) | HRH3LTA4HPTGS2PTGS1KDM4E | |
| SCHEMBL5857282 | 0.93 | HRH3 (0.97) | HRH3LTA4HPTGS2PTGS1KDM4E | |
| SCHEMBL519633 | 0.92 | LTA4H (0.91) | HRH3LTA4HPTGS2PTGS1KDM4E | |
| SCHEMBL4992188 | 0.91 | LTA4H (0.89) | HRH3LTA4HPTGS2PTGS1KDM4E | |
| SCHEMBL4557618 | 0.91 | HRH3 (0.74) | HRH3LTA4HPTGS2PTGS1KDM4E | |
| SCHEMBL521113 | 0.88 | HRH3 (0.71) | HRH3LTA4HPTGS2PTGS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131664-A1 | Method for Producing 4(3H)-Quinazolinone Derivative | MSD K.K. (JP) | 2009-05-21 | — | — | US | claimed |
| EP-1903040-A1 | METHOD FOR PRODUCING 4(3H)-QUINAZOLINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-03-26 | — | — | EP | claimed |
| US-7790731-B2 | Crystal form of 2-methyl-3-{4-[3-(1-pyrrolidinyl)propoxy]phenyl}-5-trifluoromethyl-4(3H)-quinazolinone | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7790731-B2 | Crystal form of 2-methyl-3-{4-[3-(1-pyrrolidinyl)propoxy]phenyl}-5-trifluoromethyl-4(3H)-quinazolinone | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20090131664-A1 | Method for Producing 4(3H)-Quinazolinone Derivative | MSD K.K. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20080139589-A1 | Crystal of 4(3H)-Quinazolinone Derivative | MSD K.K. (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080139589-A1 | Crystal of 4(3H)-Quinazolinone Derivative | MSD K.K. (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1903040-A1 | METHOD FOR PRODUCING 4(3H)-QUINAZOLINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-1852423-A1 | CRYSTAL OF 4(3H)-QUINAZOLINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139589-A1 | Crystal of 4(3H)-Quinazolinone Derivative | HRH3, HRH1, HRH4 | HRH3 1/4885LTA4H 1273/4885PTGS2 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.